

BRUKER BIOSCIENCES CORP

Form 8-K

April 23, 2004

[QuickLinks](#) -- Click here to rapidly navigate through this document

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **April 23, 2004**

BRUKER BIOSCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-30833
(Commission
File Number)

04-3110160
(IRS Employer
Identification No.)

40 Manning Road
Billerica, MA 01821

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(978) 663-3660**

Edgar Filing: BRUKER BIOSCIENCES CORP - Form 8-K

Item 9. Regulation FD Disclosure.

On April 23, 2004, Bruker BioSciences Corporation announced that it has priced a public offering of 15,000,000 shares of its common stock, 3,000,000 of which are being sold by the Company and 12,000,000 of which are being sold by four selling stockholders, at \$4.50 per share, generating net proceeds of approximately \$12.6 million to the Company and approximately \$50.5 million to the selling stockholders, in the aggregate. A copy of the related press release is attached hereto as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Exhibit Number	Description
-------------------	-------------

99.1	Bruker BioSciences Corporation press release dated April 23, 2004.
------	--

The information provided in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BRUKER BIOSCIENCES CORPORATION
(Registrant)

Date: April 23, 2004

By: /s/ LAURA FRANCIS

Laura Francis
Chief Financial Officer and Treasurer

Exhibit Index

Number	Description
99.1	Bruker BioSciences Corporation press release dated April 23, 2004.

QuickLinks

Item 9. Regulation FD Disclosure.

SIGNATURES

Exhibit Index